Mixed Phenotype Acute Leukemia
Conditions
Brief summary
Clinical presentation and management of Mixed-Phenotype Acute leukemia (MPAL) is heterogeneous. This descriptive observationnal study aims to review MPAL cases in the East of France based on a 10-year multicentre retrospective collection.
Interventions
None listed
Sponsors
Central Hospital, Nancy, France
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult patients over 18 years of age * Diagnosis of biphenotypic acute leukemia or mixed-phenotype acute leukemia between 2008 and 2018
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| HSCT complicated with acute and/or chronic graft-versus-host disease with severity grade and treatments for each patient | 10 years (01/01/2008-01/01/2018) | Diagnosis of GVHD according to Filipovich criterias (BMT 2005); Severity grade according to Seattle criterias; Type of treatments: steroids, other immunosuppressive agents, extracorporeal photopheresis |
| Type of treatments and dates of the first day of every treatment line for each patient | 10 years (01/01/2008-01/01/2018) | Myeloid or lymphoid chemotherapy regimen |
| Medullar response for every treatments line for each patient | 10 years (01/01/2008-01/01/2018) | Complete cytological and molecular response or treatment failure |
| Treatment including allogenic hematopoietic stem cells transplant (HSCT) (yes or no) with type of conditionning regimen for each patient | 10 years (01/01/2008-01/01/2018) | High-dose, reduced-intensity or nonmyeloablative conditioning regimens with or without total body irradiation |
| Age of the patients when diagnosed with MPAL | At inclusion (Day 0) | Age in years |
| Sex of the patients when diagnosed with MPAL | At inclusion (Day 0) | Male or female |
| City of the hematology unit in charge of each patient for the treatment of MPAL | At inclusion (Day 0) | Nancy, Metz-Thionville, Reims, Strasbourg, Mulhouse, Dijon or Besançon |
| MPAL rate in the each hematology unit | 10 years (01/01/2008-01/01/2018) | Rate of MPAL out of the total number of patients diagnosed with acute leukemia in each hematology unit |
| Date of MPAL diagnosis for each patient | At inclusion (Day 0) | — |
| Type of MPAL for each patient | At inclusion (Day 0) | De novo MPAL or secondary to myelodysplasia MPAL |
| Percentage of blood blasts for each patient at diagnosis of MPAL | At inclusion (D0) | On the first blood sample analyzed |
| Percentage of medullar blasts for each patient at diagnosis of MPAL | At inclusion (Day 0) | On the first bone marrow sample analyzed |
| Cytologic characteristics: type of myeloid markers at diagnosis for each patient | At inclusion (Day 0) | Presence or not of myeloid markers generally sought in the diagnosis of acute leukaemias |
| Cytologic characteristics: type of B lymphoid markers at diagnosis for each patient | At inclusion (Day 0) | Presence or not of B lymphoid markers generally sought in the diagnosis of acute leukaemias |
| Cytologic characteristics: type of T lymphoid markers | At inclusion (D0) | Presence or not of T lymphoid markers generally sought in the diagnosis of acute leukemias |
| Medullar MPO positivity percentage at diagnosis for each patient | At inclusion (Day 0) | If performed on the bone marrow sample used to confirm the diagnosis |
| Genetic characteristics on the caryotype at diagnosis for each patient | At inclusion (Day 0) | Presence or not of caryotypic abnormalities generally sought in the diagnosis of acute leukemias |
| Genetic characteristics on molecular biology analysis at diagnosis for each patient | At inclusion (D0) | Presence or not of molecular biology abnormalities generally sought in the diagnosis of acute leukemias |
| Classification of biphenotypic acute leukemia (BAL) according to the EGIL 1998 criterias at diagnosis | At inclusion (Day 0) | BAL or not |
| Classification of MPAL according to the WHO 2008 criterias at diagnosis | At inclusion (Day 0) | MPAL or not |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Date of death if occured | 10 years (01/01/2008-01/01/2018) | — |
| Cause of death | 10 years (01/01/2008-01/01/2018) | Secondary to leukemia, treatment or other cause |
| Date of every relapse for each patient | 10 years (01/01/2008-01/01/2018) | — |
Outcome results
None listed